Enlivex Therapeutics Ltd. (ENLV) Granted Two US Patents Covering Methods of Treating Sepsis with Allocetra

May 5, 2022 8:38 AM EDT
Get Alerts ENLV Hot Sheet
Price: $4.64 +5.94%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each patent provides Enlivex with added intellectual property (IP) protection in the United States until at least 2036 with respect to claims covering methods of treating sepsis with AllocetraTM.

Oren Hershkovitz, PhD, CEO of Enlivex, stated, “These latest patents add important depth to the IP portfolio protecting our sepsis program, with one specifically covering the treatment of sepsis derived from pneumonia, urinary, or biliary tract infections. These are three important sepsis subtypes that we intend to evaluate in our Phase II trial of Allocetra™. As we continue to advance this trial and our other programs, we plan to pursue additional patents in key geographies around the world to help maximize the value of our pipeline.”

Enlivex is developing AllocetraTM as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with other therapeutic agents.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News